Branded

ATLANTA — Antibiotic-resistant bacteria sicken more than 2 million people per year and kill at least 23,000, according to a new study by the Centers for Disease Control and Prevention.

And the costs go beyond human health and life. According to a study by Tufts University, direct healthcare costs and costs to society for lost productivity from the infections could be as high as $55 billion per year.

NEW YORK — A drug for treating opioid dependence has been launched, the manufacturer said Monday.

Orexo announced the introduction of Zubsolv (buprenorphine; naloxone) sublingual tablets for the maintenance treatment of opioid dependence. The drug is designed for use as part of a broader treatment regimen that combines drug therapy and counseling.

SILVER SPRING, Md. — Companies that make long-acting opioid painkillers will be required to conduct studies to assess their safety, while use of the drugs will be restricted, under new requirements from the Food and Drug Administration.

The agency announced new labeling changes and regulatory requirements for makers of extended-release and long-acting opioids, citing the risk the drugs carry of overdose, abuse and withdrawal. In response, a group also cautioned consumers to be careful when using non-steroidal anti-inflammatory drugs.

LEXINGTON, Mass. — Cubist has completed its purchase of Trius Therapeutics, Cubist said.

The $704 million acquisition will give Cubist control of the drug tedizolid phosphate, an experimental drug that it said had the potential to treat resistant infections. Trius ceased to be traded on the NASDAQ earlier this week.

WOODCLIFF LAKE, N.J. — Drug maker Eisai has launched a new support and savings program for patients using a weight-loss drug that it makes.

The drug maker announced Thursday the availability of Believe Everyday Support for patients using Belviq (lorcaserin hydrochloride), which includes a customizable online portal designed to help patients reach their weight loss goals and sustain their efforts.

NEW YORK — While pertussis is often considered a childhood disease, a new study from GlaxoSmithKline indicates it's a lot more common among older adults than commonly reported.

ABBOTT PARK, Ill. — Dow Jones has named Abbott an industry group leader in its 2013 Dow Jones Sustainability Index, Abbott said Thursday.

The drug maker said it achieved the top spot among healthcare companies and was one of only 24 companies selected for leading their respective industries, chosen from among 3,000 companies worldwide.

WASHINGTON — A vaccine to slow the progression of HIV and a monoclonal antibody that protects against influenza are among the nearly 300 vaccines under development by drug makers in the United States, according to a new report by a drug industry trade group.